연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
1637. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Kim R1, Hahn S2,3, Shin J1, Ock CY1, Kim M1, Keam B1,4, Kim TM1,4, Kim DW1,4, Heo DS1,4.
Cancer Res Treat. 2015 Nov 17. doi: 10.4143/crt.2015.359. [Epub ahead of print]
Link
1636. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Cho KM1,2, Keam B1,3, Kim TM1,3, Lee SH1,3, Kim DW1,3, Heo DS1,3.
Korean J Intern Med. 2015 Nov;30(6):891-8. doi: 10.3904/kjim.2015.30.6.891. Epub 2015 Oct 30.
Link
1635. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
Keam B1, Lee SJ, Kim TM, Paeng JC, Lee SH, Kim DW, Jeon YK, Chung DH, Kang KW, Chung JK, Heo DS.
J Thorac Oncol. 2015 Aug;10(8):1189-94. doi: 10.1097/JTO.0000000000000569.
Link
1634. VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma.
Park S1, Nam SJ2, Keam B1, Kim TM1, Jeon YK2, Lee SH1, Hah JH3, Kwon TK3, Kim DW1, Sung MW3, Heo DS1, Bang YJ1
Cancer Res Treat. 2015 Jul 14. doi: 10.4143/crt.2015.093. [Epub ahead of print]
Link
1633. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
Keam B1,2, Kim SB3, Shin SH4, Cho BC5, Lee KW6, Kim MK7, Yun HJ8, Lee SH1,2, Yoon DH3, Bang YJ1,2.
Cancer. 2015 Aug 1;121(15):2612-7. doi: 10.1002/cncr.29401. Epub 2015 Apr 22.
Link
1632. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Keam B1, Kim S2, Ahn YO2, Kim TM1, Lee SH1, Kim DW1, Heo DS3.
Anticancer Res. 2015 Jan;35(1):175-82.
Link
1631. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
Kim M1, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, Lee JS, Jeon YK, Kim CW, Heo DS.
Ann Hematol. 2015 Mar;94(3):437-44. doi: 10.1007/s00277-014-2228-4. Epub 2014 Oct 11.
Link
1630. Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.
Han JJ1, Kim DW2, Koh J3, Keam B1, Kim TM1, Jeon YK3, Lee SH1, Chung DH3, Heo DS1.
Clin Lung Cancer. 2015 Dec 1. pii: S1525-7304(15)00270-3. doi: 10.1016/j.cllc.2015.11.006. [Epub ahead of print]
Link
1629. The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer.
Lee JK1, Kim DW2, Keam B2, Kim TM2, Lee SH2, Kim YJ3, Heo DS2.
Cancer Res Treat. 2015 Apr;47(2):182-8. doi: 10.4143/crt.2013.227. Epub 2014 Sep 12.
Link
1628. Collateral ventilation quantification using xenon-enhanced dynamic dual-energy CT: differences between canine and swine models of bronchial occlusion.
Park EA, Goo JM, Park SJ, Lee CH, Park CM.
Korean J Radiol. 2015 May-Jun;16(3):648-656.
Link